🟢 Icecure Medical is trading 6% up today after China approved ProSense for commercialization

Icecure Medical is trading at $2.27 (+6.07%) after receiving China NMPA Class III approval for its ProSense cryoablation system and associated cryoprobes.

• The regulatory milestone expands Icecure Medical’s addressable market and enables commercialization.
• It is the clearest catalyst for the September 11, 2026 gain; broader markets are also higher, but the company-specific approval appears more directly relevant.